Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy

Clinical Chemistry

Volumn 41, Issue 3, 1995, Pages 430-434

  Yu, He ^a,b   Diamandis, Eleftherios P ^a,b,c   Prestigiacomo, Anthony F ^d   Stamey, Thomas A ^d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fluorescence immunoassay; monitoring therapy; tumor markers

Indexed keywords

ALKALINE PHOSPHATASE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH;

EID: 0028966418     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/41.3.430     Document Type: Article

References (27)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA Cancer J Clin 1992;42:19-28.
2. National Cancer Institute of Canada. Canadian Cancer Statistics 1993. Toronto, Canada: Canadian Cancer Society, 1993.
3. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-8.
4. Steele GD, Winchester DP, Menck HR, Murphy GP. Clinical highlights from the national cancer data base: 1993. CA Cancer J Clin 1993;43:71-82.
5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate [Review]. J Urol 1991;145:907-23.
6. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application [Review]. Clin Chem 1993;39:181-95.
7. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
8. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
9. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
10. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-83.
11. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-7.
12. Stamey TA, Graves HCB, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149:787-92.
13. Lange PH, Lightner DJ, Medini ER, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990;144:927-32.
14. Link P, Freiha FS, Stamey TA. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991;145:532-4.
15. ® automated immunoassay of prostate specific antigen. Clin Chem 1992;38:2044-54.
16. Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993;39:2108-14.
17. Prestigiacomo AF, Stamey TA. A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol 1994;152:1515-9.
18. Stamey ZA, Fisher DA, Pandian MR, Vendely P. Prostate cancer: clinical application of a new chemiluminescent assay for detection of ultrasensitive levels of prostate specific antigen. Clinical Application Brochure No. 450. San Juan Capistrano, CA: Nichols Institute, 1993:1-6.
19. Graves HCB, Wehner N, Stamey TA. Ultrasensitive radioimmunoassay of prostate-specific antigen. Clin Chem 1992;38:735-42.
20. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. Cancer 1993;71:2031-40.
21. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:291-300.
22. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-9.
23. Vessella RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity [Editorial]. Clin Chem 1993;39:2035-9.
24. Yu H, Diamandis EP. Serum prostate specific antigen levels after radical prostatectomy and in women. J Urol (in press) 1995.
25. Iwakiri J, Grandbois K, Wehner N, Graves HCB, Stamey TA. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993;149:783-6.
26. Kamoshide S, Tsutsumi Y. Extraprostatic localization of prostate acid phosphatase and prostate specific antigen: distribution in cloacogenic glandular epithelium and sex dependent expression in human anal gland. Hum Pathol 1990;21:1108-11.
27. McNeal LE. Origin and development of carcinoma in the prostate. Cancer 1969;23:24-34.